Humanigen, Inc. – NASDAQ:HGEN

Add to watchlist

$0.036

+0.03

+17800%

Market closed

Open in 3 days

-100.00%

month

-100.00%

quarter

-100.00%

year

Market Cap	N/A
Enterprise value	N/A

P/E	-0.18
EV/Sales	N/A
EV/EBITDA	N/A
Price/Sales	1.81
Price/Book	-0.17
PEG ratio	N/A
EPS	-1.48

Revenue	1.69M
EBITDA	-51.43M
Income	-53.30M
Revenue Q/Q	-78.66%
Revenue Y/Y	-59.01%

Profit margin	-2663.69%
Oper. margin	-2577.06%
Gross margin	22.59%
EBIT margin	-2577.06%
EBITDA margin	-3027.19%

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Humanigen, Inc. (NASDAQ:HGEN): Profit margin
Jun 2022	1.03M	-30.17M	-2913.03%
Sep 2022	221K	-23.36M	-10573.3%
Dec 2022	221K	4.39M	1986.43%
Mar 2023	221K	-4.14M	-1876.47%

Humanigen Financials Estimate

Q Y

Humanigen, Inc. (NASDAQ:HGEN): Analyst Estimates
2025	43.6M	4.75M	10.91%

Analysts Price target
Financials & Ratios estimates

Humanigen, Inc. (NASDAQ:HGEN): Earnings per share (EPS)
2022-08-12	-0.3	-0.43
2022-11-14	-0.18	-0.23

Humanigen, Inc. (NASDAQ:HGEN): Debt to assets
Jun 2022	49449000	99.53M	201.29%
Sep 2022	25968000	78.37M	301.81%
Dec 2022	11195000	57.96M	517.73%
Mar 2023	5116000	54.84M	1071.95%

Humanigen, Inc. (NASDAQ:HGEN): Cash Flow
Jun 2022	-25.37M	3.47M
Sep 2022	-17.30M	-5.01M
Dec 2022	-14.57M	21.84M
Mar 2023	-7.05M	0

Humanigen alternative data

Social Media

🎓 Academy: How impactful can social media data be in investment decisions

Humanigen, Inc. (NASDAQ:HGEN): Employee count
Aug 2023	6
Sep 2023	6
Oct 2023	6
Nov 2023	6
Dec 2023	6
Jan 2024	6
Feb 2024	6
Mar 2024	6
Apr 2024	6
May 2024	6
Jun 2024	6
Jul 2024	6

Humanigen
Hedge Funds Holdings Q1 2023

2.99% -3.91%

of HGEN is owned by hedge funds

24 -17

hedge funds hold HGEN stock

2.67M -4.32M

shares is hold by hedge funds

HGEN hedge funds holdings changes

Humanigen, Inc. (NASDAQ:HGEN): Insider trades (number of shares)
Period	Buy	Sel
Oct 2023	0	386350

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Sale	18 Oct 2023	CHAPPELL DALE director, 10 percent owner, officer: Chief S.. director, 10 percent owner, off..	Common Stock, $0.001 par value	276,210	$0.01	$3,038
Sale	18 Oct 2023	CHAPPELL DALE director, 10 percent owner, officer: Chief S.. director, 10 percent owner, off..	Common Stock, $0.001 par value	75,887	$0.01	$835
Sale	18 Oct 2023	CHAPPELL DALE director, 10 percent owner, officer: Chief S.. director, 10 percent owner, off..	Common Stock, $0.001 par value	34,253	$0.01	$377
Purchase	20 May 2022	CHAPPELL DALE director, 10 percent owner, officer: Chief S.. director, 10 percent owner, off..	Common Stock, $0.001 par value	381,841	$2.23	$850,742
Purchase	20 May 2022	CHAPPELL DALE director, 10 percent owner, officer: Chief S.. director, 10 percent owner, off..	Common Stock, $0.001 par value	109,098	$2.23	$243,070
Purchase	20 May 2022	CHAPPELL DALE director, 10 percent owner, officer: Chief S.. director, 10 percent owner, off..	Common Stock, $0.001 par value	54,549	$2.23	$121,535
Purchase	19 May 2022	CHAPPELL DALE director, 10 percent owner, officer: Chief S.. director, 10 percent owner, off..	Common Stock, $0.001 par value	226,665	$2.19	$495,490
Purchase	19 May 2022	CHAPPELL DALE director, 10 percent owner, officer: Chief S.. director, 10 percent owner, off..	Common Stock, $0.001 par value	64,762	$2.19	$141,570
Purchase	19 May 2022	CHAPPELL DALE director, 10 percent owner, officer: Chief S.. director, 10 percent owner, off..	Common Stock, $0.001 par value	32,381	$2.19	$70,785
Purchase	18 May 2022	CHAPPELL DALE director, 10 percent owner, officer: Chief S.. director, 10 percent owner, off..	Common Stock, $0.001 par value	121,590	$1.96	$238,560

Status	Patent	Filling date	Issue date
Application	Application MATERIALS AND METHODS FOR TREATING CANCER Filling date: 31 Oct 2019 Issue date: 10 Feb 2022	31 Oct 2019	10 Feb 2022
Application	Application METHODS OF TREATING IMMUNOTHERAPY-RELATED TOXICITY USING A GM-CSF ANTAGONIST Filling date: 16 Jul 2021 Issue date: 27 Jan 2022	16 Jul 2021	27 Jan 2022
Application	Application METHODS OF TREATING IMMUNOTHERAPY-RELATED TOXICITY USING A GM-CSF ANTAGONIST Filling date: 19 Apr 2021 Issue date: 21 Oct 2021	19 Apr 2021	21 Oct 2021
Application	Application METHODS FOR TREATING CORONAVIRUS INFECTION AND RESULTING INFLAMMATION-INDUCED LUNG INJURY Filling date: 29 Mar 2021 Issue date: 7 Oct 2021	29 Mar 2021	7 Oct 2021
Application	Application METHODS OF TREATING IMMUNOTHERAPY-RELATED TOXICITY USING A GM-CSF ANTAGONIST Filling date: 10 Sep 2019 Issue date: 23 Sep 2021	10 Sep 2019	23 Sep 2021
Application	Application MATERIALS AND METHODS FOR TREATING CANCER Filling date: 22 Mar 2021 Issue date: 16 Sep 2021	22 Mar 2021	16 Sep 2021
Application	Application METHODS OF TREATING IMMUNOTHERAPY-RELATED TOXICITY USING A GM-CSF ANTAGONIST Filling date: 16 Jan 2021 Issue date: 2 Sep 2021	16 Jan 2021	2 Sep 2021
Application	Application EPHA3 DIRECTED CAR-T CELLS FOR TREATMENT OF TUMORS Filling date: 9 Nov 2020 Issue date: 12 Aug 2021	9 Nov 2020	12 Aug 2021
Application	Application METHODS OF TREATING IMMUNOTHERAPY-RELATED TOXICITY USING A GM-CSF ANTAGONIST Filling date: 27 Jan 2021 Issue date: 29 Jul 2021	27 Jan 2021	29 Jul 2021
Application	Application METHODS OF TREATING IMMUNOTHERAPY-RELATED TOXICITY USING A GM-CSF ANTAGONIST Filling date: 13 Nov 2020 Issue date: 6 May 2021	13 Nov 2020	6 May 2021

Humanigen
Executives

Insider	Age	Compensation
Dr. Cameron Durrant M.B.A., M.D., MBA (1960) Chairman & Chief Executive Officer	65	$2,280,000
Mr. Timothy E. Morris CPA (1961) Chief Financial Officer & Chief Operating Officer	64	$601,840
Dr. Dale Chappell M.B.A., M.D., MBA (1970) Chief Scientific Officer & Director	55	$479,910

Humanigen
Latest News

Monday, 23 December 2024
17:22	US says former Humanigen chief scientific officer charged with insider trading	reuters.com
Tuesday, 5 March 2024
12:15	Levi & Korsinsky, LLP Notifies Shareholders of Humanigen, Inc. (HGEN) an Upcoming Claims Deadline in a Class Action Settlement	accesswire.com
Thursday, 29 February 2024
12:30	Levi & Korsinsky, LLP Notifies Shareholders of Humanigen, Inc. (HGEN) an Upcoming Claims Deadline in a Class Action Settlement	accesswire.com
Friday, 5 January 2024
11:30	HGEN Stock Alert: Why Humanigen Just Filed for Ch. 11 Bankruptcy	InvestorPlace
Thursday, 4 January 2024
18:54	COVID-19 treatment developer Humanigen files for Chapter 11 bankruptcy	Reuters
Friday, 28 July 2023
11:34	Humanigen stock removed from S&P Total Market Index as firm faces bankruptcy	Proactive Investors
Tuesday, 25 July 2023
08:29	Why Is Humanigen (HGEN) Stock Down 72% Today?	InvestorPlace
Monday, 17 April 2023
13:43	Humanigen (HGEN) Surges on Lenzilumab Study Data for Leukemia	Zacks Investment Research
Friday, 14 April 2023
12:38	3 Hot Penny Stocks To Watch Today; Is It Time To Buy?	PennyStocks
Monday, 24 October 2022
21:21	These Were the Five Best and Worst Performing Healthcare Stocks in Q3 2022	24/7 Wall Street
Wednesday, 7 September 2022
06:55	Humanigen to Participate in H.C. Wainwright and Cantor Investor Conferences in September 2022	Newsfile Corp
Monday, 29 August 2022
09:03	Why Is Humanigen (HGEN) Stock Down 16% Today?	InvestorPlace
Friday, 12 August 2022
18:48	Humanigen Inc. (HGEN) Reports Q2 Loss, Lags Revenue Estimates	Zacks Investment Research
Thursday, 14 July 2022
13:10	Humanigen (HGEN) Plunges as COVID Study Fails to Meet Goal	Zacks Investment Research
Wednesday, 13 July 2022
15:02	HC Wainwright Downgrades Humanigen On Disappointing COVID-19 Study - What's Next	Benzinga
10:34	Why Is Humanigen (HGEN) Stock Plunging 79% Today?	InvestorPlace
08:09	Humanigen's stock tumbles 67% after sharing new clinical data for its COVID-19 treatment	Market Watch
07:52	Humanigen's Lenzilumab Disappoints In NIH-Backed COVID-19 Study	Benzinga
Tuesday, 24 May 2022
06:30	Humanigen Announces Participation and Presentation at H.C. Wainwright Global Investment Conference	Business Wire
Thursday, 5 May 2022
18:49	KaloBios Pharmaceuticals Inc. (HGEN) Reports Q1 Loss, Misses Revenue Estimates	Zacks Investment Research
Thursday, 17 March 2022
13:54	Best Penny Stocks To Buy? 4 Biotech Stocks To Watch Right Now	PennyStocks
Friday, 11 March 2022
11:03	4 Nasdaq Penny Stocks To Buy For Under $5	PennyStocks
Friday, 11 February 2022
05:55	Humanigen to Present at BIO CEO & Investor Conference	Business Wire
Wednesday, 9 February 2022
10:32	Humanigen, Cenexi Ink Manufacture Pact For COVID-19 Candidate, Lenzilumab, In France	Benzinga
Monday, 17 January 2022
13:09	KaloBios Pharmaceuticals Inc. (HGEN) Upgraded to Buy: Here's What You Should Know	Zacks Investment Research
Tuesday, 4 January 2022
05:55	Humanigen to Present at Investor Conferences January 7 and 13, 2022	Business Wire
Thursday, 2 December 2021
07:06	After FDA Rejection, Humanigen's COVID-19 Drug Hopeful Sees Some Light Of Good News	Benzinga
Wednesday, 1 December 2021
18:45	Humanigen Announces Conference Call and Webcast to Discuss Lancet Respiratory Medicine Publications and Provide a Corporate Update	Business Wire
Monday, 11 October 2021
12:53	Humanigen's Budget Impact Model Demonstrates Lenzilumab's Potential Positive Economic Value in Hospitalized COVID-19 Patients	Business Wire
Friday, 8 October 2021
03:29	Clingen to distribute Humanigen Covid treatment in Europe through managed access	Proactive Investors

Frequently Asked Questions (FAQ)

What's the price of Humanigen stock today?

One share of Humanigen stock can currently be purchased for approximately $0.04.
When is Humanigen's next earnings date?

Unfortunately, Humanigen's (HGEN) next earnings date is currently unknown.
Does Humanigen pay dividends?

No, Humanigen does not pay dividends.
What is Humanigen's stock symbol?

Humanigen, Inc. is traded on the NASDAQ under the ticker symbol "HGEN".
What is Humanigen's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Humanigen?

Shares of Humanigen can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Humanigen's key executives?
Humanigen's management team includes the following people:
- Dr. Cameron Durrant M.B.A., M.D., MBA Chairman & Chief Executive Officer(age: 65, pay: $2,280,000)
- Mr. Timothy E. Morris CPA Chief Financial Officer & Chief Operating Officer(age: 64, pay: $601,840)
- Dr. Dale Chappell M.B.A., M.D., MBA Chief Scientific Officer & Director(age: 55, pay: $479,910)
How many employees does Humanigen have?

As Jul 2024, Humanigen employs 6 workers.
When Humanigen went public?

Humanigen, Inc. is publicly traded company for more then 12 years since IPO on 31 Jan 2013.
What is Humanigen's official website?

The official website for Humanigen is humanigen.com.
Where are Humanigen's headquarters?

Humanigen is headquartered at 830 Morris Turnpike, Short Hills, NJ.
How can i contact Humanigen?

Humanigen's mailing address is 830 Morris Turnpike, Short Hills, NJ and company can be reached via phone at +973 2003100.

Humanigen, Inc.

humanigen.com

Exchange:

NASDAQ

Full time employees:

Industry:

Biotechnology

Sector:

Healthcare

Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response called 'cytokine storm'. Lenzilumab is an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF). The company is developing lenzilumab as a treatment for cytokine storm associated with COVID-19 for which it has completed a Phase 3 study and is the focus of a Phase 2/3 study sponsored by the NIH. It is also developing lenzilumab, which is also being studied in conjunction with CD19-targeted CAR-T cell therapies, as well as exploring the effectiveness of lenzilumab in other inflammatory conditions, such as acute Graft versus Host Disease in patients undergoing allogeneic hematopoietic stem cell transplantation and in eosinophilic asthma, and rheumatoid arthritis. In addition, the company focuses on studying lenzilumab for patients with chronic myelomonocytic leukemia exhibiting RAS pathway mutations. Its pipeline also includes two other Humaneered monoclonal antibodies, ifabotuzumab, which binds to EphA3, and HGEN005, which targets EMR1. Ifabotuzumab has been evaluated in a Phase 1 study of glioblastoma multiforme that showed tumor specific targeting of all known tumor sites with no normal tissue uptake. HGEN005 is being explored as a treatment for a range of eosinophilic diseases, including eosinophilic leukemia as an optimized naked antibody and as the backbone for a novel CAR-T construct. Humanigen, Inc. was incorporated in 2000 and is headquartered in Short Hills, New Jersey.

+973 2003100

830 Morris Turnpike
Short Hills, NJ 07078-2625

CIK: 0001293310
ISIN: US4448632038
CUSIP: 444863203